Drug Survival, Safety, and Effectiveness of Biologics in Older Patients with Psoriasis: A Comparison with Younger Patients-A BioCAPTURE Registry Study
| Autor: | E. L. M. ter Haar, S. E. Thomas, J. M. P. A. van den Reek, M. E. Otero, M. D. Njoo, P. M. Ossenkoppele, E. N. Kop, S. R. P. Dodemont, J. E. M. Körver, A. L. A. Kuijpers, R. J. Lindhout, R. A. Tupker, J. M. Mommers, M. A. M. Berends, M. I. A. Koetsier, M. S. de Bruin-Weller, M. B. Visch, W. P. Arnold, P. P. M. van Lümig, M. M. Kleinpenning, S. F. K. Lubeek, E. M. G. J. de Jong |
|---|---|
| Přispěvatelé: | MUMC+: MA Dermatologie (9), RS: FHML non-thematic output |
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
RISK
Biological Products EFFICACY SYSTEMIC THERAPY Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2] Treatment Outcome ADHERENCE MEDICATION Inflammatory diseases Radboud Institute for Health Sciences [Radboudumc 5] ETANERCEPT Humans Psoriasis MODERATE Pharmacology (medical) Prospective Studies Registries Geriatrics and Gerontology AGENTS Aged ADALIMUMAB |
| Zdroj: | Drugs & Aging, 39(9), 715-727. Adis International Ltd Drugs & Aging, 39, 715-727 Drugs & Aging, 39, 9, pp. 715-727 |
| ISSN: | 1170-229X |
| Popis: | Contains fulltext : 282870.pdf (Publisher’s version ) (Open Access) BACKGROUND: Psoriasis is a common inflammatory disease in any age group, but also in older patients (≥ 65 years of age). Since older patients are often excluded from clinical trials, limited data specifically on this growing population are available, e.g. regarding the safety and performance of biological treatment. AIMS: We aimed to give insight into this specific population by comparing the drug survival and safety of biologics in older patients with that in younger patients. METHODS: In this real-world observational study, data from 3 academic and 15 non-academic centers in The Netherlands were extracted from the prospective BioCAPTURE registry. Biologics included in this study were tumor necrosis factor (TNF)-α, interleukin (IL)-17, IL-12/23, and IL-23 inhibitors. Patients were divided into two age groups: ≥ 65 years and |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink